Monthly Ranibizumab Beneficial In Treatment Of Recalcitrant Neovascular AMD

Monday, April 29, 2013

Ocular Surgery News

Patients with recalcitrant neovascular age-related macular degeneration achieved visual and anatomic gains out to 1 year after receiving monthly doses of 2 mg ranibizumab, according to a recent trial.

Full Story

The photo seen below is of a patient presenting with proptosis, pain and increased intraocular pressure on the left. A corresponding MRI is below. What is the most likely diagnosis?
1. Carotid-cavernous fistula
2. Cavernous hemangioma
3. Retrobulbar hematoma
4. Thyroid eye disease
Check The Answer

CareCloud Charts For Ophthalmology
Get all of the tools you need to deliver... view product
VISUPLAN 500 Non-Contact Tonometer
The measurement of intraocular pressure ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us

AdGlare Leaderboard

Monthly Ranibizumab Beneficial In Treatment Of Recalcitrant Neovascular AMD

Comments

Quick Quiz

The photo seen below is of a patient presenting with proptosis, pain and increased intraocular pressure on the left. A corresponding MRI is below. What is the most likely diagnosis?

AdGlare RMR Ad

Featured Products

CareCloud Charts For Ophthalmology

VISUPLAN 500 Non-Contact Tonometer

Follow OphthalmologyWeb

Write for Us

AdGlare RMR2